Bone marrow transplantation for Hodgkin's disease and lymphoma.
The treatment of patients with high-dose chemotherapy and autologous transplantation for recurrent or high-risk lymphomas has greatly expanded over the past few years. With the use of new supportive care measures such as newer antibiotics and hematopoietic growth factors, the morbidity and mortality rate associated with this therapy have diminished. This in turn has allowed successful use of the therapy earlier in the disease course, with resultant increases in disease-free survival rates. Future trials will strive to utilize new therapies and supportive care measures to improve on the results even further.
Vose
J M
JM
Department of Internal Medicine, University of Nebraska Medical Center, Omaha 69189-3330.
Armitage
J O
JO
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D017024:Chemotherapy, Adjuvant; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000601:surgery*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000601:surgery*; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous
D000970:Antineoplastic Agents